This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
, No Gclids
Disease Info Card
Pathologic Vasoconstriction
Information about Pathologic Vasoconstriction: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.
Overview of Pathologic Vasoconstriction
Most recent studies have shown that Pathologic Vasoconstriction shares some biological mechanisms with anoxia, atherosclerosis, cardiovascular-diseases, cerebrovascular-accident, diabetes-mellitus, edema, heart-failure, hemorrhage, hypertensive-disease, hypotension-adverse-event, hypoxia, inflammation, ischemia, nervousness, pathological-dilatation, pulmonary-hypertension, stenosis, vasospasm.
Among the many pathways, these few ones have gauged particular interests from scientists studying Pathologic Vasoconstriction, and have been seen in publications frequently: Aging, Cell Proliferation, Coagulation, Excretion, Glomerular Filtration, Innervation, Localization, Membrane Depolarization, Muscle Contraction, Natriuresis, Pathogenesis, Platelet Aggregation, Reflex, Response To Hypoxia, Secretion, Sensitization, Smooth Muscle Contraction, Transport, Vasoconstriction, Vasodilation
Quite a number of genes have been found to play important roles in Pathologic Vasoconstriction, such as ACE, AGT, ANG, ATP6V0A2, AVP, CAT, EDN1, EDNRA, EDNRB, ELANE, GPHA2, INS, KNG1, NOS1, NOS2, NOS3, NPY, REN, SGCA. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.
In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.